Market Closed -
OTC Markets
11:58:39 2024-07-02 am EDT
|
5-day change
|
1st Jan Change
|
0.013
USD
|
-48.00%
|
|
-56.67%
|
-81.94%
|
Fiscal Period: December |
2022
|
---|
Capitalization
1 |
130
|
Enterprise Value (EV)
1 |
130.3
|
P/E ratio
|
-48.8
x
|
Yield
|
-
|
Capitalization / Revenue
|
417,875,672
x
|
EV / Revenue
|
418,843,518
x
|
EV / EBITDA
|
-97
x
|
EV / FCF
|
876,436,225
x
|
FCF Yield
|
0%
|
Price to Book
|
-127
x
|
Nbr of stocks (in thousands)
|
112,034
|
Reference price
2 |
1.160
|
Announcement Date
|
3/31/23
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
0.007057
|
0.311
|
EBITDA
1 |
-0.0609
|
-0.2869
|
-1.343
|
EBIT
1 |
-0.061
|
-0.2903
|
-1.359
|
Operating Margin
|
-
|
-4,114.09%
|
-436.98%
|
Earnings before Tax (EBT)
1 |
-0.0677
|
-0.3298
|
-1.355
|
Net income
1 |
-0.0677
|
-0.3298
|
-1.355
|
Net margin
|
-
|
-4,673.19%
|
-435.69%
|
EPS
2 |
-0.9024
|
-3.282
|
-0.0237
|
Free Cash Flow
|
-
|
-0.1869
|
0.1486
|
FCF margin
|
-
|
-2,648.45%
|
47.79%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
7/5/22
|
7/5/22
|
3/31/23
|
Fiscal Period: December |
2020
|
2021
|
2022
|
---|
Net Debt
1 |
0.06
|
-
|
0.3
|
Net Cash position
1 |
-
|
0.08
|
-
|
Leverage (Debt/EBITDA)
|
-0.9727
x
|
-
|
-0.2241
x
|
Free Cash Flow
|
-
|
-0.19
|
0.15
|
ROE (net income / shareholders' equity)
|
-
|
-1,217%
|
299%
|
ROA (Net income/ Total Assets)
|
-
|
-52.1%
|
-178%
|
Assets
1 |
-
|
0.6335
|
0.761
|
Book Value Per Share
2 |
-0.6500
|
0.9900
|
-0.0100
|
Cash Flow per Share
2 |
0.0300
|
3.900
|
0
|
Capex
1 |
0
|
0.03
|
0.03
|
Capex / Sales
|
-
|
386.98%
|
8.36%
|
Announcement Date
|
7/5/22
|
7/5/22
|
3/31/23
|
|
1st Jan change
|
Capi.
|
---|
| -81.94% | 1.46M | | +15.58% | 121B | | +16.60% | 110B | | +17.73% | 25.93B | | -24.33% | 19.27B | | -19.35% | 16.01B | | -17.95% | 15.66B | | -48.32% | 14.89B | | +58.78% | 14.47B | | +4.91% | 13.91B |
Bio Therapeutic Drugs
|